Clinical observation of pemetrexed pombined cisplaton as second-line treatment for advanced lung adenocarcinoma

Objective To explore the efficacy and toxicity of pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma.Methods 60 cases with end-stage lung adenocarcinoma who were failed treatment for nehemiah and carboplatin/taxol(CP) chemotherapy were used pemetrexed combined cisplaton AS chemotherapy from January 2009 to June 2010 in our hospital.100 ml of pemetrexed 500 mg/m2 joining 0.9% of sodium chloride were for intravenous injection,cisplatin 75 mg/m2,repeat one time each 3 weeks,completed two cycles about above chemotherapy and evaluated the clinical and toxicity.Results 1) Complete remission(CR) was 0 case,partial remission(PR) were 4 cases,stable(SD) were 35 cases and progress(PD) were 11 cases in 60 patients;the total effective was 6.7%(4/60),the rates of disease control(DCR) was 65.0%(39/60).(2) Toxicity is mainly exhaustion of 33 cases(55.0%),leukocyte fell were 26 cases(43.3%),degrees decline were 4 cases(6.7%),gastrointestinal reaction were 19 cases(31.7%),allergic reactions were 2 cases(3.3%),it did not affect chemotherapy after symptomatic treatment.Conclusion Pemetrexed combined Cisplaton AS second-line treatment for advanced lung adenocarcinoma is one of the ideal solutions.